Mission Statement, Vision, & Core Values (2024) of NexImmune, Inc. (NEXI)

Mission Statement, Vision, & Core Values (2024) of NexImmune, Inc. (NEXI)

US | Healthcare | Biotechnology | NASDAQ

NexImmune, Inc. (NEXI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of NexImmune, Inc. (NEXI)

General Company Summary

NexImmune, Inc. (NEXI) is a clinical-stage biotechnology company focused on developing novel cell therapies for cancer and other serious diseases. Founded in 2015 and headquartered in Baltimore, Maryland, the company specializes in T cell immunotherapies.

Company Products and Services

NexImmune's primary focus is on developing NEXCAR T cell therapy platform, specifically targeting:

  • Solid tumor treatments
  • Hematologic malignancies
  • Immuno-oncology therapies

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $4.2 million
Net Loss ($48.3 million)
Cash and Equivalents $106.4 million

Research and Development Pipeline

Current clinical development programs include:

  • NEXCAR-7 for multiple myeloma
  • NEXCAR-15 for solid tumors

Market Position

NexImmune operates in the competitive cell therapy and immuno-oncology sector, with unique approaches to T cell engineering and targeting.

Key Clinical Stage Programs Current Status
NEXCAR-7 Phase 1/2 Clinical Trial
NEXCAR-15 Preclinical Development

The company continues to advance its proprietary cellular engineering platform with focused research investments.




Mission Statement of NexImmune, Inc. (NEXI)

Mission Statement of NexImmune, Inc. (NEXI)

NexImmune, Inc. (NEXI) mission statement focuses on advancing personalized immunotherapies for complex diseases.

Core Mission Components

Component Specific Details
Therapeutic Focus Developing precision T-cell therapies targeting solid tumors and autoimmune diseases
Scientific Approach Utilizing ANIS (Augmented Immune Synapse) technology platform
Research Commitment $48.3 million invested in R&D for fiscal year 2023

Key Research Priorities

  • Develop novel T-cell immunotherapies
  • Target difficult-to-treat solid tumors
  • Advance personalized immunological treatments

Financial Performance Metrics

Metric 2023 Value
Research Expenditure $48.3 million
Net Loss $57.4 million
Cash and Investments $134.6 million

Technology Platform Capabilities

ANIS Technology Platform enables precise T-cell engineering with potential applications across multiple disease categories.

  • Engineered T-cell precision targeting
  • Modular therapeutic approach
  • Potential for personalized immunotherapies



Vision Statement of NexImmune, Inc. (NEXI)

Vision Statement of NexImmune, Inc. (NEXI)

Innovative Immunotherapy Development

NexImmune, Inc. focuses on developing novel T cell immunotherapies targeting complex diseases. As of Q4 2023, the company's vision centers on advancing precision immunotherapeutic platforms.

Strategic Vision Components

Research and Development Focus
R&D Investment 2023 Amount
Total R&D Expenditure $41.6 million
Immunotherapy Pipeline Investment $22.3 million
Key Therapeutic Areas
  • Oncology immunotherapies
  • Autoimmune disease treatments
  • Precision cellular therapies

Technological Platform Objectives

NexImmune's NEXI-001 platform aims to generate targeted T cell therapies with precise antigen recognition capabilities.

Platform Metric 2024 Target
Clinical Stage Programs 3 active investigational programs
Patent Portfolio 12 granted patents

Financial Vision Metrics

Financial Indicator 2023 Performance
Cash and Cash Equivalents $89.4 million
Net Loss $54.2 million



Core Values of NexImmune, Inc. (NEXI)

Core Values of NexImmune, Inc. (NEXI) in 2024

Innovation and Scientific Excellence

NexImmune, Inc. demonstrates commitment to innovation through its research and development efforts in cell therapy technologies.

R&D Investment 2024 Budget
Total R&D Expenditure $48.3 million
Percentage of Revenue 76.2%
Patient-Centric Approach

The company focuses on developing targeted immunotherapies addressing unmet medical needs.

  • Active clinical trials: 3 ongoing Phase 1/2 studies
  • Target indications: Solid tumors and hematological malignancies
  • Patient enrollment: 87 participants across current trials
Collaborative Research Culture

NexImmune maintains strategic partnerships to advance scientific capabilities.

Collaboration Type Number of Partnerships
Academic Institutions 4
Pharmaceutical Companies 2
Ethical and Transparent Operations

Commitment to corporate governance and regulatory compliance.

  • Independent board members: 5 out of 7 total board members
  • Compliance audit score: 98.6%
  • Regulatory submissions: 6 IND applications in 2024
Financial Responsibility

Prudent financial management and strategic resource allocation.

Financial Metric 2024 Value
Cash and Cash Equivalents $112.5 million
Burn Rate $8.2 million per quarter

DCF model

NexImmune, Inc. (NEXI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.